A real world, retrospective, case-control study evaluating effect of Bamlanivimab in patients with COVID-19
Latest Information Update: 16 Apr 2021
At a glance
- Drugs Bamlanivimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 16 Apr 2021 New trial record
- 13 Apr 2021 Primary endpoint (30-day hospitalization rate from initial positive SARS-CoV-2 PCR) has been met as per results published in the Clinical Infectious Diseases.
- 13 Apr 2021 Results published in the Clinical Infectious Diseases